Electroconvulsive therapy versus magnetic seizure therapy for major depression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional comparison enrolls patients aged 12–80 with DSM-5–confirmed major depressive disorder, stabilized on medication, who are indicated for neuromodulation or have visual field defects, alongside healthy controls. Participants receive either electroconvulsive therapy (ECT) or magnetic seizure therapy (MST) with repeated clinical, cognitive, and behavioral assessments. Neurophysiological measures such as EEG and resting-state fMRI are collected to characterize treatment effects and mechanisms. Tolerability, cognitive outcomes, and depressive symptoms are compared between the two intervention groups.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 12-80 years;
* Diagnosis confirmed by two psychiatrists per DSM-5;
* Stable medication regimen pre-enrollment;
* Indicated for neuromodulation OR with visual field defects.

Exclusion Criteria:

* Major systemic diseases;
* Prior neuromodulation within 3 months;
* Pregnancy or potential pregnancy;
* Metal implants or claustrophobia.

Where it's running

• Anhui Medical University
  Hefei, Anhui, China Recruiting

Study contacts

• Study coordinator: Yanghua Tian PhD
• Email: zylykd@163.com
• Phone: 0551 6599 7278

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dupilumab for Major Depressive Disorder

  This study tests whether dupilumab can engage immune targets in adults with major depressive disorder to see if it can help with depressive symptoms.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07908563

• Accelerated vs Standard iTBS for Major Depression

  This trial tests whether giving more accelerated iTBS sessions is better tolerated and more effective than the standard schedule for adults with major depressive disorder.

  Recruiting Military Hospital 175 · Ho Chi Minh City · NCT07768397

• Psilocybin with Structured Integrated Reframing Therapy for trauma-related MDD and PTSD

  This trial tests whether psilocybin therapy, alone or with Structured Integrated Reframing Therapy (SIRT), helps people with trauma-related major depressive disorder who are already on a stable antidepressant.

  Recruiting Phase 3 Khyber Medical University Peshawar · Islamabad, Capital and 2 other locations · NCT07703722

• Magnesium Bisglycinate Added to Your Depression Treatment

  This study tests whether adding magnesium bisglycinate to your current antidepressant can help reduce depressive symptoms and improve sleep and daily functioning for adults with major depressive disorder.

  Recruiting All India Institute of Medical Sciences, Bhubaneswar · Bhubaneswar, Odisha · NCT07633080

• Flumazenil to help reduce cognitive side effects during ECT for depression

  This study tests whether giving flumazenil to reverse benzodiazepine effects during electroconvulsive therapy can lower cognitive side effects without reducing treatment effectiveness in adults with depression.

  Recruiting Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital · Frederiksberg, Capital Region · NCT07619092

• Motif XCS System for treatment-resistant depression

  This study tests whether the Motif XCS System is safe and tolerable and might help people with treatment-resistant major depressive disorder.

  Recruiting at 4 sites Motif Neurotech, Inc. · Atlanta, Georgia and 3 other locations · NCT07594483

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.